Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study
Open Access
- 18 July 2011
- journal article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 11 (1), 196
- https://doi.org/10.1186/1471-2334-11-196
Abstract
Background During the 2009 influenza A/H1N1 pandemic, adjuvanted influenza vaccines were used for the first time on a large scale. Results on the effectiveness of the vaccines in preventing 2009 influenza A/H1N1-related hospitalisation are scanty and varying. Methods We conducted a matched case-control study in individuals with an indication for vaccination due to underlying medical conditions and/or age ≥ 60 years in the Netherlands. Cases were patients hospitalised with laboratory-confirmed 2009 A/H1N1 influenza infection between November 16, 2009 and January 15, 2010. Controls were matched to cases on age, sex and type of underlying medical condition(s) and drawn from an extensive general practitioner network. Conditional logistic regression was used to estimate the vaccine effectiveness (VE = 1 - OR). Different sensitivity analyses were used to assess confounding by severity of underlying medical condition(s) and the effect of different assumptions for missing dates of vaccination. Results 149 cases and 28,238 matched controls were included. It was estimated that 22% of the cases and 28% of the controls received vaccination more than 7 days before the date of onset of symptoms in cases. A significant number of breakthrough infections were observed. The VE was estimated at 19% (95%CI -28-49). After restricting the analysis to cases with controls suffering from severe underlying medical conditions, the VE was 49% (95%CI 16-69). Conclusions The number of breakthrough infections, resulting in modest VE estimates, suggests that the MF-59™ adjuvanted vaccine may have had only a limited impact on preventing 2009 influenza A/H1N1-related hospitalisation in this setting. As the main aim of influenza vaccination programmes is to reduce severe influenza-related morbidity and mortality from influenza in persons at high risk of complications, a more effective vaccine, or additional preventive measures, are needed.Keywords
This publication has 32 references indexed in Scilit:
- Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trialThe Lancet Infectious Diseases, 2011
- Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control StudyPLoS Medicine, 2011
- Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in KoreaVaccine, 2011
- Age-Specific Effectiveness of an Oil-in-Water Adjuvanted Pandemic (H1N1) 2009 Vaccine Against Confirmed Infection in High Risk Groups in EnglandThe Journal of Infectious Diseases, 2011
- Vaccines for preventing influenza in the elderlyCochrane Database of Systematic Reviews, 2010
- Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trialThe Lancet, 2010
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineNew England Journal of Medicine, 2009
- Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjectsInternational Journal of Clinical Practice, 2009
- Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complicationsJournal of Epidemiology and Community Health, 2002